Trial Profile
A Phase I, Randomized, Placebo-Controlled, Double-Blind, Ascending-Dose And Single-Center Study To Evaluate Immunogenicity And Safety Of A Live Attenuated Tetravalent Dengue Vaccine (KD-382) In Flavivirus Antibody-Nave Healthy Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Mar 2021
Price :
$35
*
At a glance
- Drugs KD-382 (Primary)
- Indications Dengue
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors Kaketsuken; KM Biologics
- 25 Mar 2021 Results presented in a KM Biologics media release.
- 20 Sep 2020 Status changed from active, no longer recruiting to completed.
- 05 Aug 2019 Planned End Date changed from 30 Apr 2020 to 30 Sep 2020.